Skip to main content
News Icon

News categories: Honors & Funding

Patent-Prize awarded for programing of stem cells into Photoreceptors

Discovery and utilization of three different transcription factors enables the directed differentiation of human stem cells into photoreceptors

Prof. Volker Busskamp, Member of the Cluster of Excellence ImmunoSensation2, is awarded with the Patent-Prize of the German Ophthalmological Society for his work on photoreceptors. The Biotechnologist and his team developed a technology, which allows the rapid programming of human stem cells to become photoreceptors. The resulting cells are used in retinal research and shall serve in clinical application to treat blindness in the near future.

Photoreceptors are sensory cells of the eye, located in the retina. They enable seeing by detection of the incoming light and its translation into electrochemical signals. Degeneration or loss of photoreceptor cells, as in macular degeneration, retinitis pigmentosa or retinal detachment, leads to vision impairment or even blindness.

Volker Busskamp and his team established a reliable method to quickly generate photoreceptor cells, which was now awarded with the Patent-Prize of the German Ophthalmological Society. The award honors inventions with patent pending and supports outstanding concepts in Ophthalmology.

The awarded method is based on the discovery and utilization of three different transcription factors, which induce the differentiation of human stem cells into photoreceptors. In the Petry-dish, the cells grow into light-sensitive receptor cells within several days. The method allows for the generation of vast amounts of cell material. This is of particular relevance, as the retina itself does not possess any regenerative potential. The possibility to generate human photoreceptors in the Petry-dish hence opens new prospects in basic research, drug screening, but also clinical application: The possible utilization of the photoreceptors in photoreceptor-replacement therapy is already under investigation.

Prof. Busskamp and his team are involved in the technology transfer supported by a ‘proof-of-concept’ grand of the European Research Council. In the end, a biomedical application of human stem cells programmed into photoreceptors is supposed to be part of an innovative therapy to treat all sorts of photoreceptor-degeneration associated diseases.


Contact

Prof. Dr. Volker Busskamp

Universitäts-Augenklinik Bonn

Tel.: +49 228 287-13687

E-Mail: volker.busskamp(at)ukbonn.de


Related news

Prof. Dr. Kaan Boztug

News categories: Honors & Funding

Kaan Boztug awarded Novartis Prize

Prof. Dr. Kaan Boztug from the University Hospital Bonn (UKB) receives the Novartis Prize for Therapy-Relevant Immunological Research 2025. The expert in rare diseases of the immune system and blood formation conducted most of the research work that has now been honored in Vienna. His work was supported by an ERC Starting Grant (ImmunoCore, 2012-2018) and an ERC Consolidator Grant (iDysChart, 2019-2025), among others. The science prize, worth 10,000 € is divided into two parts this time and also goes to Prof. Dr. Evelyn Ullrich.
View entry
Niklas Klümper

News categories: Honors & Funding

Niklas Klümper Receives Johann-Georg-Zimmermann Prize

PD Dr. Niklas Klümper was honored with the prestigious Johann-Georg-Zimmermann Research Prize. The €10,000 award is presented annually to young cancer researchers for their current scientific contributions.
View entry
Speakers of ImmunoSensation

News categories: Honors & Funding

ImmunoSensation goes into the next round

The Bonn Cluster of Excellence ImmunoSensation will be funded for further seven years as part of the Excellence Strategy of the German federal and state governments. The aim of the new funding period, which begins on January 1, 2026, is to research immune diversity: the structural, functional and dynamic diversity of the immune system. Involved are the University of Bonn, the University Hospital Bonn (UKB) and the German Center for Neurodegenerative Diseases (DZNE). The funding amounts to around 50 million euros.
View entry

Back to the news overview